Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2022

View Archived Issues

Extracellular domains are not effective targets to disrupt intracellular HER2-HER3 tumor signaling

CECR2 promotes breast cancer metastasis through NF-kappaB signaling and immunosuppression

Neumora licenses rights to novel M4 receptor PAMs from Vanderbilt for schizophrenia

Monoclonal antibodies in AR-701 cocktail neutralize SARS-CoV-2 Omicron variant

New coagulation factor XIa inhibitors synthesized at Janssen Pharmaceutica

Merck & Co. presents new adenosine A2A and/or A2B receptor antagonists

New SREBP inhibitors identified at Capulus Therapeutics

Fog Pharmaceuticals describes stapled peptides targeting beta-catenin

New HSD17B13 inhibitors identified at Inipharm

Neurophilin-1 is an inhibitor of HIV-1 infectivity

Broadly neutralizing HCV antibodies isolated from high responders used to design new antibody

Using photoactivatable peptide toxins for modulation of voltage-gated ion channels

Nrf2 agonists ameliorate anemia of inflammation by disrupting the hepcidin-ferroportin axis

Targeting GDNF may have potential to treat IBD

New biomarkers identified to predict response to vedolizumab in patients with Crohn's disease

Targeting PFKFB3 reduces the severity of colitis in mouse models

EBV antibodies put to good use through retargeting

Mindset reports new benchmarking data on first-generation psychedelics

Repertoire Immune Medicines and UMass Chan collaborate to understand immune causes of vitiligo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.